Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Newsletter 2022

Newsletter July 2022: Clinical corner - Case report: A rare encounter with 'Stiff Person Syndrome' patient for day-care procedure

Cheah Kean Seng (MBBS, FCAI), David Chiang (MBBS, MMed Anaes)


Case description:

We encountered an interesting case of a 52 year-old lady with underlying ‘Stiff Person Syndrome’ (SPS) scheduled for day-care upper gastrointestinal scope and colonoscopy. She was diagnosed with SPS in 2018 with Hashimoto Thyroiditis and chronic headache. She is taking Baclofen, Myonal, Paracetamol and Celebrex for her SPS and Euthyroxin for hypothyroidism. Her manifestation of SPS was usually painful spasticity of limbs triggered by anxiety and pain.

We successfully managed her case with monitored sedation throughout the procedure. The approach mainly focused on ensuring adequate depth of sedation and avoiding her triggering factors (anxiety and pain). She was given a local anaesthesia spray prior to cannulation in a calm, quiet induction room. Premedication Midazolam 2mg was given prior to the procedure. We maintained her sedation with target-controlled infusion (TCI) propofol at 1.5mcg/ml. Abolus of fentanyl 25mcg was given before the surgeon proceeded with colonoscopy. She went through both upper and lower GI scopes without any spasm or rigidity. She remained well, pain-free and asymptomatic in the recovery bay and she was discharged home the same day.


SPS, sometimes known by the name Stiff man Syndrome (SMS) was first described by Moersch & Woltman in a case report in 1956. It is a rare autoimmune neurological syndrome manifested by fluctuating rigidity and painful spasm of axial or limb muscle¹. The mechanism of the stiffness remains unknown but is likely autoimmune driven due to the presence of antibodies against glutamic acid decarboxylase (rate-limiting enzyme for the synthesis of GABA) in cerebrospinal fluid. GABA has inhibitory input to muscle producing relaxation effects. The imbalance caused by low GABA from autoimmune will eventually lead to continual motor activation and muscle spasm. During an exacerbation, the presentation can be easily mistaken as a seizure or anxiety attack (reported in previous case reports). Prolonged hypotonia or weakness post-operation can also be mistaken for acetylcholinesterase deficiency if suxamethonium was used during anaesthesia. Successful treatment of this condition has been directed at the enhancement of GABA-ergic neurotransmission, mainly Baclofen at doses from 20-200mg per day ², steroids or immunosuppressive drugs.

As uncommon as it seems to be but when it comes to the time of anaesthesia, the ‘dos’ and the ‘don’ts’ during anaesthesia have a direct relation to patient outcome. Only very limited case reports can be found in the literature regarding anaesthetic management of SPS patients. Anaesthesiologists will face two spectrums of challenges from SPS patients with either risk of muscle spasm versus prolonged weakness.

Muscle relaxant: The administration of muscle relaxant and a volatile agent has been previously known to cause prolonged hypotonia in SPS patients. Johnson & Miller first reported that their patient had prolonged hypotonia with vecuronium use which lead to 48 hours of ventilation despite the adequate reversal of muscle relaxantᶟ. Five months later with the same procedure, they did not encounter any complications after avoidance of muscle relaxantᶟ. This effect was not reported by Haslam & Price with the use of atracurium in their patient for two separate occasions⁴. The antibodies responsible for SPS have no effect on the neuromuscular junction therefore muscle relaxants should not cause post-op weakness. This was objectively assessed by Obara et al. with train of four ratio (TOF) in an SPS patient. When the neuromuscular monitor was used during the case, it demonstrates recovery of the train of four ratio (TOF) to 100% post-operation, suggesting that muscle relaxation has no effects in SPS patient⁵. Yamamoto further consolidated this finding by assessing neuromuscular junction in the absence of muscle relaxant, which found no effect as well⁶. However, interpretation of TOF itself can be difficult if used in patients with abnormal muscle tone. If muscle relaxant is necessary during anaesthesia, it is more suitable to use those that can be fully reversed by Sugammadex such as Vecuronium/Rocuronium.

Volatile agent: Bouw et al. later attributed the observation made by Johnson & Miller due to the effects of a volatile agent with Baclofen treatment in an SPS patient. The majority of patients are taking Baclofen as treatment pre-operatively and if a volatile agent was used during anaesthesia, the presence of Baclofen will amplify the GABA (b)-ergic effects of volatile. Bouw claimed that their patient who was on Baclofen pre-operatively had prolonged ventilation for 1 hour with 0.6-1% of Isoflurane use⁷. This relation between volatile agent and baclofen can be dose-related because in one case report by Qin et al who used a lower concentration of Isoflurane (0.2-0.4%) along with nitrous oxide and remifentanyl infusion, they found no complications in their patient⁸.

Several case reports have been published on the successful management of SPS patients in surgery without the complication of flare-ups. Yamamoto K et al combined general and epidural anaesthesia for their patient who had undergone thymectomy⁶. The use of epidural is beneficial for superior pain management and reduced the impact of anaesthesia with GABAergic action.

If general anaesthesia is required for surgery, total intravenous anaesthesia (TIVA) is superior to conventional volatile agent plus muscle relaxant because there have been case reports demonstrating a  good outcome⁹.

Spinal and regional anaesthesia is advocated to be the best choice if deemed appropriate for the nature of surgery. Nabil et al. performed a paravertebral block with conscious sedation for their SPS patient undergone inguinal hernia repair successfully¹⁰. However, this method can be tricky and challenging due to the risk of spasms induced by pain during needle entry, or patient anxiety from situation awareness. Therefore, one must pay attention to non-pharmacological management in SPS patients including reassurance, ensuring a calm environment, avoiding sudden loud auditory stimulation, and good pain and anxiety management for the patient.

  • Consent was obtained from the patient for the publication of this case report.


  1. Brown P, Marsden CD. J Neurol. 1999 Aug; 246(8):648-52.
  2. Howard FM Jr. Mayo Clin. 1963 May 22; 38:203-12.
  3. Johnson JO, Miller KA. Anesth Analg 80: 612-613.
  4. Haslam N, Price K. Anaesthesia 57: 298-299.
  5. Obara M, Chinzei M, Komatsu K, et al. Anaesthesia 57: 511.
  6. Yamamoto K, Hara K, Horishita T et al. J Anesth 21: 490-492.
  7. Bouw J, Leendertse K, Tijssen MAJ et al. Anesth Analg. 2003 Aug; 97(2):486-487.
  8. Qin X, Wang D, Wu X. Chin Med J 119(11): 963-965.
  9. Ledowski T, Russell P. Anaesthesia. 2006 Jul; 61(7):725.
  10. Elkassabany N, Tetzlaff JE, Argalious M. J Clin Anesth. 2006 May; 18(3):218-20.

[maxbutton id=”1″ url=”https://www.esaic.org/newsletter/” text=”Read the Newsletter” ]

Related news

See all news